

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8102116

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	DEUTERX, LLC	01/12/2022
RECEIVING PARTY DATA		
Name:	SALARIUS PHARMACEUTICALS, INC.	
Street Address:	2450 HOLCOMBE BLVD	
Internal Address:	SUITE X	
City:	HOUSTON	
State/Country:	TEXAS	
Postal Code:	77021	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16956741
CORRESPONDENCE DATA		
Fax Number:	(617)570-1231	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	16175701000	
Email:	US-PatentBos@goodwinlaw.com, CMcCarty@goodwinlaw.com, KChadwick@goodwinlaw.com, JasonWilliams@goodwinlaw.com	
Correspondent Name:	GOODWIN PROCTER LLP	
Address Line 1:	100 NORTHERN AVENUE	
Address Line 2:	IP DOCKETING DEPT./7TH FL	
Address Line 4:	BOSTON, MASSACHUSETTS 02210	
ATTORNEY DOCKET NUMBER:	SLU-023	
NAME OF SUBMITTER:	CATHERINE M. MCCARTY	
SIGNATURE:	/Catherine M. McCarty/	
DATE SIGNED:	08/08/2023	
Total Attachments: 6		
source=Salarius_-_DeuteRx_Patent_Assignment_Agreement_(Execution_Copy)#page1.tif		
source=Salarius_-_DeuteRx_Patent_Assignment_Agreement_(Execution_Copy)#page2.tif		
source=Salarius_-_DeuteRx_Patent_Assignment_Agreement_(Execution_Copy)#page3.tif		

source=Salarius_-_DeuteRx_Patent_Assignment_Agreement_(Execution_Copy)#page4.tif

source=Salarius_-_DeuteRx_Patent_Assignment_Agreement_(Execution_Copy)#page5.tif

source=Salarius_-_DeuteRx_Patent_Assignment_Agreement_(Execution_Copy)#page6.tif

PATENT

REEL: 064523 FRAME: 0907

EXECUTION COPY**PATENT ASSIGNMENT AGREEMENT**

This Patent Assignment Agreement (***“Patent Assignment Agreement”*** or ***“Agreement”***) is made and entered into as of January 12, 2022 (the ***“Effective Date”***) by and between **DEUTERX, LLC**, a Delaware limited liability company (***“Seller”***) and **SALARIUS PHARMACEUTICALS, INC.**, a Delaware corporation (***“Purchaser”***). Seller and Purchaser are sometimes referred to herein, individually, as a ***“Party”*** and, collectively, as the ***“Parties.”***

WHEREAS, Seller is the owner of certain patents and patent applications (as set forth in **Exhibit F** attached to the ASCA (as defined below) and reproduced at the end of this Patent Assignment Agreement) (the ***“Assigned Patents”***); and

WHEREAS, pursuant to that certain Acquisition and Strategic Collaboration Agreement between Seller and Purchaser dated as of January 12, 2022 (the ***“ASCA”***), Seller has agreed to sell, convey, assign and transfer to Purchaser all right, title and interest of Seller in and to the Assigned Patents.

NOW, THEREFORE, in consideration of the foregoing premises and of other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. **Assignment of Patents.** Seller hereby irrevocably and unconditionally sells, assigns, transfers, conveys and delivers to Purchaser, and Purchaser hereby accepts, all right, title and interest that exist today or may exist in the future in, to and under the Assigned Patents, the inventions disclosed in the Assigned Patents and in and to all letters patent and other patent rights of the United States of America and all other jurisdictions which may or shall be granted on said inventions, or any parts thereof, and any divisionals, continuations, continuations in part, continuing prosecution applications, requests for continuing examinations, reexaminations, extensions, reissues, supplementary protection certifications or other applications or registrations based in whole or in part on said inventions or Assigned Patents, all rights to apply in any or all countries of the world for patents, certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances of any type related to any of the foregoing, and the right to all causes of action (known, unknown, currently pending, filed, or otherwise) and other enforcement rights under, or on account of, any of the Assigned Patents, including the ability to recover damages, obtain injunctive relief, and/or any other remedies available for past, present or future infringement and all rights to recover damages (including attorney’s fees and expenses) or lost profits in connection therewith and all rights to collect and receive consideration, compensation, reward, royalties or other payments under, or on account of, the Assigned Patents; all of the same to be held and enjoyed by Purchaser, for its own use and the use of its successors, legal representatives, assigns and nominees, as fully and entirely as the same would have been held and enjoyed by Seller had this assignment not been made.

2. **Recording of Patent Assignment.** Seller does hereby request and authorize the United States Patent and Trademark Office Commissioner for Patents and all other applicable governmental entities, registrars, patent offices or authorities of other jurisdictions to issue letters patent, certificates of invention, utility models, or other governmental grants or issuances that may

be granted upon any of the Assigned Patents and the inventions disclosed in the Assigned Patents to Purchaser or Purchaser's nominee, successor, legal representative or assign.

3. **Further Assurances.** Seller agrees to execute all specific assignments, oaths, declarations, deeds or other instruments and to take any other necessary acts, in each case, that are reasonably requested by Purchaser, and at Purchaser's sole expense, (a) to transfer to Purchaser, and vest in Purchaser the legal title to, the Assigned Patents, (b) to secure the grant of letters patent on the Assigned Patents and the inventions disclosed in the Assigned Patents in the jurisdictions set forth in **Exhibit F** to the ASCA, and (c) as otherwise as may be required for obtaining, maintaining, extending, reissuing, enforcing or defending the Assigned Patents throughout the world.

4. **Asset Acquisition and Collaboration Agreement.** This Patent Assignment Agreement is entered into pursuant to and is subject in all respects to the terms, provisions and conditions of the ASCA, and nothing herein shall be deemed to modify, supersede, enlarge, limit or affect the rights of the Parties under the ASCA. If any provision of this Patent Assignment Agreement conflicts with the provisions of the ASCA, the provisions of the ASCA shall control.

5. **Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof.


6. **Counterparts; Electronic Execution.** This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party may execute this Agreement by facsimile transmission or in Adobe™ Portable Document Format (PDF) sent by electronic mail. Facsimile or PDF signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement.

7. **Successors and Assigns.** This Agreement shall inure to the benefit of, and be binding upon, the Parties and their respective successors and assigns.

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

IN WITNESS WHEREOF, the Parties have caused this Patent Assignment Agreement to be executed by their duly authorized representatives as of the day and year first above written.


DEUTERYX LLC

By:  _____
8E610540E60P449...

Name: Sheila Dewitt

Title: President & CEO

SALARIUS PHARMACEUTICALS, INC.

By:  _____
69688FE4124D4AE...

Name: David Arthur

Title: Chief Executive Officer

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

Assigned Patents

DEUTERATED IMiDs (d-CC-11006 & d-CC-220) 2',6'-Dioxo-3'-deutero-piperidin-3-yl-isoindoline compounds								
Docket	Subcase	Status	Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
DEU-006	PR	Expired	61/468179	28-Mar-2011				
DEU-006	WO	NATIONALIZED	PCT/US12/030870	28-Mar-2012				
DEU-006	AU	Granted - Abandoned	2012236655	28-Mar-2012		2012236655	42740	
DEU-006	CA	Granted - Abandoned	2867134	28-Mar-2012		2867134	43592	
DEU-006	DE	Granted - Abandoned	12764895.4	28-Mar-2012	2699091	60 2012 033 728.1	42907	
DEU-006	EP	Granted / Opposed / Revoked	12764895.4	28-Mar-2012	2699091	2699091	42907	
DEU-006	FR	Granted	12764895.4	28-Mar-2012	2699091	2699091	42907	
DEU-006	GB	Granted	12764895.4	28-Mar-2012	2699091	2699091	42907	
DEU-006		Granted	13/432382	28-Mar-2012	US-2012-0252844	9090585	42213	Mar 2032
DEU-006	C1	Abandoned	14/744493	19-Jun-2015	US-2016-0002202-A1			
DEU-006	C2	Abandoned	15/722187	02-Oct-2017	US-2018-0118712-A1			
DEU-006	C3	Abandoned	16/044816	25-Jul-2018				
DEUTERATED CC-122 (including DRX-164) 3-(5-Substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione, related compounds, and methods of use								
Docket	Subcase	Status	Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
DEU-007	PR	Expired	61/752055	14-Jan-2013				
DEU-007	PR2	Expired	61/786024	14-Mar-2013				
DEU-007	WO	NATIONALIZED	PCT/US2014/011440	14-Jan-2014	WO2014/110558			
DEU-007	AU	Granted	2014205043	14-Jan-2014		2014205043	43482	Jan 2034
DEU-007	CA	Granted	2935495	14-Jan-2014		2935495	44306	Jan 2034
DEU-007	EP	Granted / Opposed / Regranted	14737860.8	14-Jan-2014	2943201	2943201	43166	Jan 2034
DEU-007	JP	Granted	2015-552887	14-Jan-2014		6359563	43280	Jan 2034
DEU-007	JPD1	Granted	2018-116936	14-Jan-2014		6749364	44056	Jan 2034

PATENT

REEL: 064523 FRAME: 0911

DEU-007		Granted Withdrawn Regranted	/ /	14/154743	14-Jan-2014	US-2014-0228382-A1	9540340	42745	Jan 2034
DEU-007	C1	Abandoned		14/873900	02-Oct-2015				
DEU-007	C2	Abandoned		15/342385	03-Nov-2016				
DEU-007	C3	Granted		15/379908	15-Dec-2016	US-2017-0158579-A1	10202316	43508	Jan 2034
DEU-007	C4	Granted		16/222280	17-Dec-2018	US-2019-0330124-A1	11040925	44369	Jan 2034
DEU-007	C5	Pending		17/323482	18-May-2021				
DEUTERATED CC-122 REGIOISOMERS (6-, 7-, and 8-substituted)3-(Substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero piperidine-2,6-dione derivatives and methods of use									
Docket	Subcase	Status		Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
DEU-009	PR	Expired		61/7786111	14-Mar-2013				
DEU-009	WO	NATIONALIZED		PCT/US14/27918	14-Mar-2014	WO2014/152833			
DEU-009	AU	Abandoned		2014236597	14-Mar-2014				
DEU-009	CA	Pending		2941560	14-Mar-2014				Mar 2034
DEU-009	EP	Abandoned		14769837.7	14-Mar-2014	2968334			
DEU-009		Granted		14/211889	14-Mar-2014	US-2014-0288101-A1	9290475	42451	Mar 2034
DEU-009	C1	Granted		15/064895	09-Mar-2016	US-2016-0287590-A1	9913845	43172	Mar 2034
DEU-009	C2	Granted		15/809107	10-Nov-2017		10555946	43872	Mar 2034
DEU-009	C3	Pending		16/716662	17-Dec-2019				Mar 2034
DEUTERATED CC-220									
Deuterium-enriched oxo-isoindolinonyl-piperidinonyl-2,6-diones and methods of use									
Docket	Subcase	Status		Application #	Filing Date	Publication #	Patent #	Issue Date	
DEU-014	PR	Expired		61/955488	19-Mar-2014				
DEUTERATED IMIDS CONJUGATED TO PROTEIN BINDING MOIETY (e.g. d-DBET1, d-ARV-825)									
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of use									
Docket	Subcase	Status		Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
DEU-020	PR	Expired		62/206396	18-Aug-2015				
DEU-020		Granted		15/240499	18-Aug-2016		9809603	43046	Aug 2036
DEU-020	C1	Granted		15/783129	13-Oct-2017	US-2018-0118758-A1	10189858	43494	Aug 2036
DEUTERATED ISOINDOLINE COMPOUNDS (including d-CC-90009)									
Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of use									
Docket	Subcase	Status		Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
DEU-021	PR	Expired		62/402084	30-Sep-2016				

PATENT

REEL: 064523 FRAME: 0912

DEU-021		Abandoned	15/720262	29-Sep-2017				
DEU-021	C1	Abandoned	16/244218	10-Jan-2019				
DEU-021	C2	Pending	16/992674	13-Aug-2020				Sep 2037
DEUTERATED PROTACS (POMALIDOMIDE CONJUGATED TO DASATINIB, BOSUTINIB, etc.) Deuterium-enriched isoindolinonyl-piperidinonyl conjugates, related compounds, and methods of use								
Docket	Subcase	Status	Application #	Filing Date	Publication #	Patent #	Issue Date	
DEU-022	PR	Expired	62/433898	14-Dec-2016				
DEU-022		Abandoned	15/841889	14-Dec-2017				
DEUTERATED ISOINDOLINONYL-AZEPANEDIONES AND METHODS (e.g. d-PHMs) Deuterium-enriched isoindolinonyl-azepanediones, related compounds, and methods of use								
Docket	Subcase	Status	Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
DEU-023	PR	Pending	62/609446	22-Dec-2017				
DEU-023	WO	NATIONALIZED	PCT/US2018/067199	21-Dec-2018				Dec 2038
DEU-023		Pending	16/956741	22-Jun-2020				
DEUTERATED CC-99282 AND RELATED ANALOGS Deuterium Substituted Analogs of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione								
Docket	Subcase	Status	Application #	Filing Date	Publication #	Patent #	Issue Date	Expiry Date
		Invention Summary Memorandum		15-Nov-2021				

PATENT

REEL: 064523 FRAME: 0913

RECORDED: 08/08/2023